<- Go Home
Genitope Corp.
On September 1, 2020, Genitope Corp. went out of business as per its Chapter 7 liquidation filing under bankruptcy. Genitope Corp., a biotechnology company, offers research and development of immunotherapies for the treatment of cancer in the United States. Immunotherapies are treatments that utilize the immune system to combat diseases. It develops a panel of monoclonal antibodies for the treatment of Non-Hodgkin’s Lymphoma. The company was founded in 1996 and is based in Fremont, California.
Market Cap
$64.5K
Volume
542.4K
Cash and Equivalents
$11.6M
EBITDA
-$53.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.00
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.01
Price / Earnings
-0.00
Price / Tangible Book Value
0.01
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$61.3M
Return on Equity
210.59%
Return on Assets
-36.77
Cash and Short Term Investments
$12.4M
Debt
$47.5M
Equity
$10.1M
Revenue
N/A
Unlevered FCF
-$26.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium